Netland P A, Schwartz B, Feke G T, Takamoto T, Konno S, Goger D G
Department of Ophthalmology, University of Tennessee, Memphis 38163, USA.
J Glaucoma. 1999 Jun;8(3):164-71.
This randomized, double-masked, placebo-controlled, two-period crossover study was conducted to investigate the effects of 0.5% timolol maleate in gel-forming solution on intraocular pressure (IOP) and blood circulation in the optic nerve head in patients with untreated ocular hypertension.
The effects of 0.5% timolol in gel-forming solution on IOP and optic nerve head capillary blood speed were studied in 12 patients with untreated ocular hypertension. Optic nerve capillary blood speed was measured using the laser Doppler technique before and at the end of each treatment period.
In each patient, IOP decreased after treatment with timolol (mean decrease 16.8% versus placebo). Systemic blood pressure and pulse rate did not differ significantly after treatment with topical timolol from values after placebo. The mean change from baseline in Doppler broadening was 10.6% greater after treatment with timolol than after placebo. There was no significant change in mean Doppler broadening from baseline after treatment with either timolol or placebo. However, optic nerve head capillary blood speed increased in six patients, and was within the range of placebo response in six patients after treatment with timolol. Spearman correlation analysis of the baseline with Doppler broadening measurements after treatment showed a correlation for placebo but not for timolol. The percent change in Doppler broadening after timolol treatment was correlated with iris color.
These results indicate that administration of timolol for 4 weeks reduces IOP in patients with ocular hypertension and generally does not change the blood circulation in the optic nerve head. Individual patients, however, showed variable changes in optic nerve head circulation after topical administration of timolol. Although the sample size was small, these changes in optic nerve head circulation were correlated with iris color.
本随机、双盲、安慰剂对照、两阶段交叉研究旨在调查0.5%马来酸噻吗洛尔凝胶制剂对未经治疗的高眼压症患者眼压(IOP)及视神经乳头血液循环的影响。
研究了0.5%马来酸噻吗洛尔凝胶制剂对12例未经治疗的高眼压症患者眼压及视神经乳头毛细血管血流速度的影响。在每个治疗阶段开始前及结束时,使用激光多普勒技术测量视神经毛细血管血流速度。
每位患者使用噻吗洛尔治疗后眼压均下降(平均下降16.8%,与安慰剂相比)。局部使用噻吗洛尔治疗后,全身血压和脉搏率与使用安慰剂后的值相比无显著差异。使用噻吗洛尔治疗后,多普勒增宽相对于基线的平均变化比使用安慰剂后大10.6%。使用噻吗洛尔或安慰剂治疗后,多普勒增宽相对于基线均无显著变化。然而,6例患者的视神经乳头毛细血管血流速度增加,使用噻吗洛尔治疗后6例患者的血流速度在安慰剂反应范围内。治疗后多普勒增宽测量值与基线的Spearman相关性分析显示,安慰剂组有相关性,而噻吗洛尔组无相关性。噻吗洛尔治疗后多普勒增宽的变化百分比与虹膜颜色相关。
这些结果表明,噻吗洛尔给药4周可降低高眼压症患者的眼压,且一般不会改变视神经乳头的血液循环。然而,个别患者局部使用噻吗洛尔后,视神经乳头循环出现了不同变化。尽管样本量较小,但这些视神经乳头循环的变化与虹膜颜色相关。